Royal Bank of Canada cut its holdings in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 57.1% in the first quarter, HoldingsChannel reports. The firm owned 26,937 shares of the company’s stock after selling 35,896 shares during the period. Royal Bank of Canada’s holdings in TransMedics Group were worth $2,678,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of TMDX. Goldman Sachs Group Inc. raised its holdings in TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after buying an additional 322,353 shares in the last quarter. Two Sigma Investments LP boosted its stake in shares of TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after acquiring an additional 223,409 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of TransMedics Group by 100.5% during the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company’s stock worth $52,713,000 after acquiring an additional 217,180 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of TransMedics Group by 43.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company’s stock valued at $69,338,000 after acquiring an additional 171,810 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of TransMedics Group by 11.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after acquiring an additional 113,817 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at TransMedics Group
In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.
Analyst Upgrades and Downgrades
View Our Latest Report on TransMedics Group
TransMedics Group Stock Performance
Shares of TransMedics Group stock opened at $88.58 on Monday. TransMedics Group, Inc. has a 52-week low of $60.10 and a 52-week high of $156.00. The firm has a market capitalization of $3.06 billion, a PE ratio of 22.77 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The company’s fifty day moving average price is $75.65 and its two-hundred day moving average price is $96.65.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group’s revenue was up 20.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.92 earnings per share. On average, analysts expect that TransMedics Group, Inc. will post 1.47 EPS for the current year.
TransMedics Group Profile
TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.
TransMedics currently markets two commercially available OCS platforms.
Featured Articles
- Five stocks we like better than TransMedics Group
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
